Evotec (EVO) announced the nomination of a small molecule preclinical development candidate from its multi-target drug discovery alliance in medical dermatology with Almirall. The program is aimed at developing novel treatments for immune-mediated inflammatory skin diseases with high unmet medical need. Evotec will continue to support the program toward IND submission through its INDiGO platform, an integrated, accelerated IND-enabling platform designed to ensure a transition from discovery to clinical readiness.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on EVO:
- Evotec Strengthens Supervisory Board and Strikes Governance Pact With MAK Capital
- Evotec receives two grants for tuberculosis drug discovery, translation
- Evotec Announces CFO Transition as Hitchin Departs and Hinshelwood Steps In
- Evotec CFO Paul Hitchin to step down, Claire Hinshelwood to succeed
- Evotec assumed with a Buy at H.C. Wainwright